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Summary. Plasma levels o f A N F were determined 
and chromatographically analysed in normo-
tensive controls, cirrhotic patients wi th and wi th -
out ascites, hypertensive patients, patients wi th 
congestive heart failure and heart transplant re-
cipients. A comparison o f baseline plasma levels 
allowed for the conclusion that cirrhotic patients 
do not differ in this regard from control subjects 
(9.0+ 1.3, η = 41 vs. 9 . 6 ± 1,0 f m o l / m l , n = 5l). Cir­
rhotic patients wi th ascites do not have lower 
plasma levels than cirrhotic patients without as­
cites (8.8+1.4, n = S vs 8.6+1.5 fmo l /ml , η =10). 
Stimulation o f the ANF-system by head-out water 
immersion, however, revealed an impaired i n ­
crease in A N F release in cirrhotic patients wi th as­
cites (146+ 18% vs 204+ 16%). Patients wi th car­
diovascular disease display tonically-elevated A N F 
plasma levels. Heart failure patients displayed the 
highest plasma concentration (81.5 ± 32.7 fmo l / 
ml , n = 17), whereas plasma levels in hypertensive 
patients ranged from normal to greatly elevated 
(61.7+ 13.2 fmo l /ml , a = 36). Heart transplant re­
cipients also had significantly elevated plasma 
levels as compared to control subjects (31.2+7.9 
fmol /ml , η = 14) but levels were lower than in hy­
pertensive patients in spite o f a comparable ar­
terial pressure. Short term ventricular pacing 
( / = 1 5 0 / m i n for 5 min) revealed an impaired 
phasic activity o f the A N F system in heart failure 
patients and heart transplant recipients. Two hy­
pertensive patients without hypertensive heart dis­
ease displayed an increase to 367% o f baseline 
levels immediately subsequent to ventricular pac­
ing, heart transplant recipients showed an increase 
to 207+ 22% above baseline whereas the response 
in heart failure patients was significantly less 
(134+ 13%). The molecular weight pattern in 
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transplant patients did not differ from heart fai l­
ure patients prior to pacing; in heart failure, how­
ever, pacing may induce a release o f higher 
molecular weight forms o f A N F . 
Key Words: At r i a l Natriuretic Factor - Stimulus-
Response-Coupling - Ventricular Pacing, Water 
Immersion - Heart Failure - Hypertension -
Heart Transplantation - Cirrhosis 
Peters and Gauer regarded the atria as being "the 
ideal site to sense the fullness o f the blood stream" 
[23, 12]. Since the work o f Henry and Gauer the 
atria have been known to bear volume/stretch-
sensitive receptors [13, 17]. Wi th the discovery o f a 
natriuretic hormone in the atria ( A N F ) , the mam­
malian heart acquired an endocrine function and 
A N F has emerged as a good candidate for the me­
diation o f atrial distention-induced natriuresis. I n 
distinction to other natriuretic hormones [8, 18, 
20] i t was not unreasonable to suppose that natr i ­
uretic hormone o f atrial origin ( A N F ) should pos­
sess vasodilator properties [7, 24] enabling the 
heart to adapt to changes i n extracellular volume 
(ECV) and blood pressure, thereby op t imiz ing its 
performance by an appropriate ANF-effected de­
crease in pre- and after-load [1]. 
Remarkably quickly following the discovery o f 
A N F , its molecular biology and physiology could 
be unravelled [5, 11, 21], and A N F plasma levels 
have been determined and characterized in var i ­
ous disease states [3, 14]. However, baseline plas­
ma levels as such may not satisfactorily reflect the 
functional status and compensatory reactivity o f 
the endocrine heart to alterations i n volume/pres­
sure homeostasis. A tonically-maintained high 
plasma level might induce a receptor down-regu­
lation or be associated wi th other adaptive chang­
es [5] and, paradoxically, eventually prove physi-
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ologically counter-productive. Further, the dy-
namics, responsiveness and magnitude o f rapid 
and transient phasic alteration in A N F could be 
compromised in the case o f a sustained very high 
rate o f release. To investigate the phasic response 
of the A N F system to acute, rapid and transient 
s t imul i we subjected, firstly, patients suffering 
from cardiovascular diseases and displaying 
chronically elevated levels o f A N F to short-term 
ventricular pacing and, secondly, cirrhotic patients 
showing normal levels o f A N F to head-out water 
immersion. 
Methods 
Extraction o f plasma samples and R I A procedures 
were modified from [2] and have been detailed 
elsewhere [4]. Briefly, antibody Toni I I I is m id -
molecule- and C-terminal directed. Cross reac-
tivi ty has been reported previously [4]. The final 
titer was 1:120000 and the assay sensitivity was 
0.5 fmol/assay tube. The 50%-binding intercept o f 
the standard curve was 15 fmol. Synthetic stan-
dard was from Nova Biochem, Läufelfingen, Swit-
zerland. 0.5 or 1 ml-plasma aliquots were ex-
tracted by adsorption to prerinsed Amberli te 
X A D - 2 adorbent resin [2]. Recovery o f synthetic 
A N F 9 9 _ 1 2 6 was approximately 67%. The intra-
assay coefficient o f variation (a? = 6) was < 10%. 
Plasma extracts were subjected to high perfor-
mance gel permeation chromatography (HPGPC) 
on a 7.5X600 m m TSK-125 Bio Sil column (Bio 
Rad, Munich , FRG) , eluted wi th 0.09% T F A con-
taining 0.005 Μ N a 2 S 0 4 plus 0.002 Μ N a H 2 P 0 4 
and 30% acetonitrile as a solvent. Flow rate was 
0.4 m l / m i n , and aliquots from column fractions 
were analyzed for immunoreactive ( i r ) -ANF. Ir-
A N F following HPGPC was quantitated as 3 sepa­
rate peaks coeluting wi th the void volume (69-kd-
A N F ) , ra t -Pro-ANF (15-kd- A N F ) , and human 
A N F 9 9 _ 1 2 6 (3 -kDa-ANF) . Results following 
HPGPC are given as % o f total i r - A N F . Peripheral 
blood was drawn into pre-cooled syringes and i m ­
mediately transferred to pre-cooled polystyrene 
tubes containing 500 kall ikrein inhibi tor un i t s /ml 
aprotinin and l m g sodium E D T A . Plasma was 
separated and stored at - 7 0 ° C unt i l extraction. 
Fifty normotensive control subjects showing 
no evidence o f cardiovascular, renal, pulmonary 
or gastrointestinal disease, 36 patients wi th hy­
pertension, 17 patients wi th congestive heart fail­
ure, 14 heart transplant recipients and 41 cirrhotic 
patients agreed to participate in the study. Heart 
transplant recipients were on immunosuppressive 
and antihypertensive therapy but remained hy­
pertensive ( M A P 1 1 5 ± 3 m m H g ) . 
Fourteen heart transplant recipients, 5 patients 
wi th congestive heart failure and 2 hypertensive 
patients (MAP 120 and 125 m m H g ) undergoing 
diagnostic heart catheterization were subjected to 
right ventricular pacing (3mA, f = 1 5 0 / m i n for 
5 min) after giving their informed consent. Venous 
blood was sampled prior to and immediately fol­
lowing electrostimulation. 
22 healthy controls and 18 cirrhotic patients 
were subjected to head-out water immersion pro­
cedures. Cirrhotic patients were divided into sub­
groups wi th and without ascites. After voiding, 
subjects assumed a seated position next to the i m ­
mersion tank for the first hour o f the experiment. 
Subsequently, they were immersed up to their 
necks, maintaining the same seated position in 
thermoneutral water (35 .0± 0.2° C) for 1 hour fol­
lowed by an additional hour sitting outside the 
tank. Throughout the experiment 250 m l / h r o f tap 
water was given orally. A l l patients were on a reg­
ular hospital diet. Data are presented as means 
± S.E.M. Statistical analysis was performed by 
Student's unpaired or paired t-test. 
Experimental protocols were approved by the 
institutional committee on the ethics o f human in ­
vestigation. 
Results 
Baseline ANF-plasma levels are given in table I . 
Whereas i r - A N F failed to differ between nor­
motensive controls and cirrhotic patients, i t may 
be seen that levels were significantly elevated in 
patients with cardiovascular disease. Hypertensive 
patients displayed a sixfold increase in plasma 
A N F as compared to normotensive controls. A 
subgroup of untreated patients wi th essential hy­
pertension had comparably high levels. Patients 
wi th congestive heart failure displayed an 8-fold 
increase in plasma-ANF. Plasma concentrations in 
heart transplant recipients were 3-fold higher than 
in control subjects but significantly lower than in 
hypertensive patients (p < 0.01). 
To evaluate the phasic response o f the A N F 
system, cardiovascular patients were subjected to 
right ventricular pacing, a stimulus established to 
elicit a release o f A N F [22]. Further, cirrhotic pa­
tients were subjected to head-out water immersion 
for augmentation o f central venous pressure [6, 10, 
15]. Thereby stimulated A N F plasma levels are 
given in table I I . Electric pacing in heart trans­
plant recipients increased i r - A N F to 207 ± 2 2 % 
(/? < 0.01) o f baseline levels. I n comparison, ir-
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A N F in patients wi th congestive heart failure in ­
creased to 134± 13% o f baseline levels. This i n ­
crease was significantly less than in heart trans­
plant recipients (p< 0.01) and considerably lower 
than in 2 hypertensive patients, in which i r - A N F 
levels increased to 367% o f baseline values. 
I n control subjects, head-out water immersion 
induced an increase i n A N F plasma levels to 
207 ± 30% following 1 hour o f immersion. The i n ­
crease in A N F plasma levels was accompanied 
by a marked renal response. Urinary sodium 
excretion increased from 0.16 ± 0 . 0 2 to 
0.31 + 0.03 m m o l / m i n and the volume of urine 
from 1.57 ± 0 . 2 5 to 5.28 ± 0.63 m l / m i n . The in ­
crease in A N F concentrations seen in cirrhotic pa­
tients without ascites ( 2 0 4 ± 1 6 % o f basal values) 
did not differ from that i n normal subjects. How­
ever, cirrhotic patients with ascites displayed a 
lesser increase in A N F plasma levels to 1 4 6 ± 18%. 
This difference was paralleled by a lower increase 
in sodium excretion. Sodium excretion in cirrhot­
ics without ascites increased by 0.11 ± 0.04 m m o l / 
m i n as compared to cirrhotic patients wi th ascites 
(by 0 .07± 0.02 m m o l / m i n ) . Urine volume in pa­
tients without ascites increased by 2 . 3 4 ± 0 . 8 m l / 
min and in cirrhotics wi th ascites by 
0 . 6 5 ± 0 . 3 2 m l / m i n . 
A n ini t ial structural analysis o f plasma A N F 
was performed by use o f HPGPC in plasma ex­
tracts o f 5 normotensive controls, 11 hypertensive 
and 13 patients wi th congestive heart failure. A 
cumulative analysis revealed that in controls 
8 ± 5 % o f total i r - A N F eluted as 69-kd-ANF as 
compared to 1 6 ± 6 % in hypertensive patients or 
6 ± 2 % in heart failure patients (not significant). 
However, in heart failure patients, 1 8 ± 3% o f total 
i r - A N F co-eluted wi th the main peak from rat 
atrial extract (Pro-ANF or 15-kd-ANF); this por­
tion was significantly greater (/?<0.05) than in 
control subjects or in hypertensive subjects (5 ± 2 
or 9 ± 2 % ) . More severely compromised patients 
tended to display higher amounts o f 15-kd-ANF. 
The chromotographic analysis o f i r - A N F in a 
single, heart transplant recipient prior and sub­
sequent to ventricular pacing is depicted in Fig. 1. 
I t may be seen that the main fraction elutes as low 
molecular weight-ANF, in addition, two earlier 
peaks can clearly be separated. As yet, a total o f 4 
heart tansplant recipients have been thus ana­
lysed: 1 6 . 2 ± 7 . 4 % or i r - A N F eluted as 15-kd-
A N F ; following pacing this fraction decreased 
slightly to 1 3 . 0 ± 4 . 2 % . Conversely, a patient wi th 
congestive heart failure displayed an increase 
from 3 to 12% in 15-kd-ANF following electrical 
pacing. 
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Fig. 1. Molecular weight pattern of i r - A N F in a single heart 
transplant recipient prior to (upper panel) and subsequent to 
(lower panel) ventricular pacing. The TSK-125 Bio Sil chroma­
tography system separates compounds in accordance with their 
respective molecular size. V 0 =void volume, bovine serum 
albumin; V t = total volume, 3 H-glycin; r P r o - A N F = rat 
A N F i - i 2 6 ; C D D - 8 8 = bovine A N F i - 88 (gift from Professor 
Forssmann, Heidelberg); h ANF-28 = human ANF99_i26- The 
molecular weight standards are indicated by arrows. 
Discussion 
Notwithstanding intensive study, mechanism o f 
disturbed renal sodium handling i n patients wi th 
cirrhosis are not, as yet, completely understood. I t 
has been hypothesized that a failure to adequately 
elaborate a natriuretic hormone contributes to 
sodium retention in cirrhotics [9, 19]. However, 
our data demonstrate that baseline plasma levels 
o f A N F in cirrhotic patients are not lower than in 
healthy counterparts (table 1). 
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I t is possible, that despite the expanded ex­
tracellular volume i n cirrhotics, splanchnic 
sequestration o f fluids may prevent an increase in 
central volume and atrial pressure, and thus re­
lease may not be adequate to counteract the vol­
ume overload. I t has, however, been reported that 
massive ascites may actually increase atrial pres­
sure and thus should constitute a stimulus for 
A N F release [16]. However we were unable to 
demonstrate a difference in basal plasma levels 
between cirrhotic patients wi th and without ascites 
(table 2). Indeed, i t may not be possible from an 
analysis o f plasma levels alone to convincingly ad­
dress the fol lowing questions: Firstly, is a stimulus 
which instigates a release o f A N F in normal 
healthy subjects similarly capable of accelerating 
the secretion o f A N F i n cirrhotics? Secondly, is the 
A N F secretion elicited quantitatively adequate to 
exercise a functional effect? Thirdly, is the i r - A N F 
- material actually comprised o f authentic ANF? 
Essentially, the central issue is as to whether the 
increased level o f A N F in cirrhotic patients is suf­
ficient to exert the desired effect i n the target tis­
sues. We and other have previously demonstrated 
that head-out water immersion in normotensive 
controls is an effective stimulus for A N F release 
[10, 15]. Water immersion elicits an increase i n 
right atrial pressure via a distribution o f blood to 
the intrathoracic venous bed [6] and may thereby 
evoke an increase i n the release o f A N F . As may 
Table 1. ANF-Immunoreactivity in Plasma 
M e a n ± S . E . M . 
[fmol/ml] 
Normotensive controls (n = 50) 9.6 ± 1.0 
Hyertensive patients (n = 36) 61.7+13.2* 
Congestive heart failure patients (n = 17) 81.5 ± 3 2 . 7 * 
Heart transplant recipients (n — 14) 3 1 . 2 ± 7.9* 
Cirrhotic patients (n = 41) 9 . 0 ± 1.3° 
° n.s., */?<0.01, t-test 
Table 2. Stimulus-response-coupling of A N F 
be seen from table I I , there was no difference i n 
the response to water immersion between controls 
and cirrhotic patients without ascites. On the other 
hand, there was a blunted increase o f A N F se­
cretion in those cirrhotic patients exhibiting as­
cites. This diminished elevation in A N F cor­
responded to a blunted renal response (electrolyte 
secretion and urine volume) to immersion. In i t ia l 
chromatographic analysis revealed no qualitative 
difference in the pattern o f i r - A N F between cir­
rhotic patients and their normotensive counter­
parts [4]. The renal response, i n this study, tended 
to be suppressed i n the cirrhotic group, but not 
significantly so. 
I n contrast, patients suffering from various 
types o f cavdiovascular disease (see table 1) 
manifested considerably elevated plasma levels o f 
i r - A N F . The rise in the heart transplant group, 
was significantly lower than i n the hyper­
tensive patients although both groups dis­
played a comparable elevation in arterial pres­
sure. The relatively lower levels in the transplant 
group may reflect the absent innervation of the 
grafted heart or be a consequence o f i m ­
munosuppressive therapy. 
In spite o f overall, tonically elevated plasma 
levels in cardiovascular disease, the secretory atri­
al apparatus in these patients may, in fact, have 
surrendered its ability to react phasically to rapid, 
transient stimuli wi th a further facilitation of re­
lease. I n addition, tonically maintained high plas­
ma levels might result in a down-regulation o f tar­
get receptors. Ventricular pacing mimics a rapid 
and transient increase in atrial pressure by atrial 
'plugging' (Vorhofpfropfung) [22]. Pacing was per­
formed in congestive heart failure patients, heart 
transplant recipients and 2 hypertensive patients 
without hypertensive heart disease exhibiting un­
altered baseline levels o f A N F . As shown in table 
2, A N F levels rose significantly i n transplanted 
patients, whereas the increase in heart failure pa-
Before After 
[fmol/ml [fmol/ml] 
a. ) Ventricular pacing 
Heart transplant recipients (n = 14) 
Congestive heart failure (n = 5) 
Hypertensive patients with normal baseline levels (n-
b. ) Water immersion 
Control subjects (n = 22) 
Cirrhotic patients without ascites (n = 10) 
Cirrhotic patients with ascites (n = 8) 
•2) 
3 1 . 2 ± 7.9 




8 . 8 ± 1.4 
54.8 ± 1 1 . 9 * * 
5 1 . 6 ± 8.0° 
26.8 
13 .9± 2.8* 
16 .8± 2.9* 
12 .8± 2.4 
not significant, ** /?<0 .01 , * p<0.05, paired t-test 
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tients failed to achieve Statistical significance. I n 
both heart failure patients and transplant recipi­
ents the response was significantly less pro­
nounced as i n the 2 hypertensive patients. This 
may suggest that the ability o f the A N F secretory 
mechanism to react to a phasic stimulus is 
compromised i n heart failure and transplant re­
cipients. 
We have previously demonstrated that the 
molecular weight pattern o f i r - A N F i n patients 
wi th cardiovascular disease can differ from that in 
normotensive subjects suggesting a modification 
o f post-translational processing o f A N F [4]. I n the 
present study, in which a larger population o f pa­
tients were examined, the molecular weight pat­
tern o f i r - A N F also significantly differed from that 
shown by control subjects. 18% of total i r - A N F 
was comprised o f 15-kd-ANF (Pro-ANF?) i n heart 
failure patients. Four heart transplant recipients as 
yet analysed revealed a similar pattern: however 
subsequent to pacing this fraction decreased 
slightly whereas in one heart failure patient pacing 
even led to an increase in 15-kd-ANF. 
We conclude that an analysis o f baseline plas­
ma levels o f A N F may allow for the detection o f 
an altered level of secretion o f atrial secretory ap­
paratus. However, in the presence of tonically ele­
vated plasma levels in the pathological states o f 
heart failure and transplant the phasic ability o f 
the A N F system (perhaps physiologically more 
important) to swiftly react to transient st imuli may 
be impaired. In addition, heart failure patients 
may also show a qualitatively altered molecular 
pattern o f A N F secretion. As performed here, a 
quantitative and qualitative (chromatographic) 
analysis o f stimulated A N F plasma levels may 
eventually prove of value in the biochemical 
classification o f heart disease. 
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